Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neuronetics (NASDAQ: STIM), a medical technology and healthcare company focused on neurohealth therapies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Keith Sullivan, President and CEO, will deliver a presentation on Tuesday, August 12, 2025, at 1:30 PM ET.
The presentation will be accessible to registered attendees and presenting companies through the conference portal for 14 days following the event.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica e sanit脿 specializzata in terapie per la neuro-salute, ha annunciato la sua partecipazione alla prossima 45陋 Conferenza Annuale sulla Crescita di Canaccord Genuity. Keith Sullivan, Presidente e CEO, terr脿 una presentazione marted矛 12 agosto 2025 alle 13:30 ET.
La presentazione sar脿 disponibile per i partecipanti registrati e le aziende presentatrici tramite il portale della conferenza per 14 giorni dopo l'evento.
Neuronetics (NASDAQ: STIM), una empresa de tecnolog铆a m茅dica y atenci贸n sanitaria centrada en terapias para la neuro-salud, ha anunciado su participaci贸n en la pr贸xima 45陋 Conferencia Anual de Crecimiento de Canaccord Genuity. Keith Sullivan, Presidente y CEO, realizar谩 una presentaci贸n el martes 12 de agosto de 2025 a la 1:30 PM ET.
La presentaci贸n estar谩 accesible para los asistentes registrados y las empresas presentadoras a trav茅s del portal de la conferencia durante 14 d铆as despu茅s del evento.
Neuronetics (NASDAQ: STIM)電� 鞁犼步 瓯搓皶 旃橂鞐� 欷戩爯鞚� 霊� 鞚橂 旮办垹 氚� 項姢旒�鞏� 須岇偓搿�, 瓿� 鞐措Μ電� Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐� 彀胳棳頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟. Keith Sullivan 靷灔 瓴� CEO臧� 2025雲� 8鞗� 12鞚� 頇旍殧鞚� 鞓ろ泟 1鞁� 30攵� ET鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
氚滍憸 雮挫毄鞚� 霌彪霅� 彀胳劃鞛� 氚� 氚滍憸 旮办梾霌れ澊 旎嵓霟办姢 韽劯鞚� 韱淀暣 頄夓偓 膦呺 頉� 14鞚缄皠 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Neuronetics (NASDAQ : STIM), une entreprise de technologies m茅dicales et de soins de sant茅 sp茅cialis茅e dans les th茅rapies neuro-sant茅, a annonc茅 sa participation 脿 la prochaine 45e Conf茅rence Annuelle de Croissance de Canaccord Genuity. Keith Sullivan, Pr茅sident et CEO, fera une pr茅sentation le mardi 12 ao没t 2025 脿 13h30 ET.
La pr茅sentation sera accessible aux participants inscrits et aux entreprises pr茅sentant via le portail de la conf茅rence pendant 14 jours apr猫s l'茅v茅nement.
Neuronetics (NASDAQ: STIM), ein Unternehmen f眉r Medizintechnik und Gesundheitswesen mit Schwerpunkt auf Neurogesundheitstherapien, hat seine Teilnahme an der bevorstehenden 45. j盲hrlichen Wachstumskonferenz von Canaccord Genuity angek眉ndigt. Keith Sullivan, Pr盲sident und CEO, wird am Dienstag, den 12. August 2025, um 13:30 Uhr ET eine Pr盲sentation halten.
Die Pr盲sentation wird f眉r registrierte Teilnehmer und pr盲sentierende Unternehmen 眉ber das Konferenzportal f眉r 14 Tage nach der Veranstaltung zug盲nglich sein.
- None.
- None.
MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day.
The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event.
础产辞耻迟听狈别耻谤辞苍别迟颈肠蝉
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world鈥檚 largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO庐 (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
Media Contact:
EvolveMKD
646-517-4220
FAQ
When is Neuronetics (STIM) presenting at the Canaccord Genuity Growth Conference?
Who will be presenting for Neuronetics at the Canaccord Conference?
How long will the Neuronetics (STIM) presentation be available after the conference?
What is Neuronetics' (STIM) main business focus?
